We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+39.3%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$77.2M
Cap. Flow
+$48M
Cap. Flow %
21.55%
Top 10 Hldgs %
25.3%
Holding
464
New
223
Increased
67
Reduced
60
Closed
103

Top Buys

Rank Stock Value
1
MOH icon
Molina Healthcare
MOH
+$8.43M
2
ELV icon
Elevance Health
ELV
+$5.15M
3
INTC icon
Intel
INTC
+$4.26M
4
SNDK
Sandisk
SNDK
+$3.61M
5
JNJ icon
Johnson & Johnson
JNJ
+$3.5M

Top Sells

Rank Stock Value
1
IEF icon
iShares 7-10 Year Treasury Bond ETF
IEF
+$4.82M
2
UNH icon
UnitedHealth
UNH
+$3.15M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$2.87M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.84M
5
LH icon
Labcorp
LH
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 52.36%
2 Technology 13.57%
3 Financials 11.27%
4 Communication Services 4.48%
5 Energy 3.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
201
Vaxcyte
PCVX
$8.12B
$246K 0.11%
5,334
-44,742
-89% -$2M
UPB
202
Upstream Bio Inc
UPB
$381M
$242K 0.11%
+8,907
New +$222K
LIVN icon
203
LivaNova
LIVN
$4.43B
$241K 0.11%
+3,911
New +$223K
DXCM icon
204
DexCom
DXCM
$29.6B
$239K 0.11%
+3,600
New +$233K
AAOI icon
205
Applied Optoelectronics
AAOI
$8.22B
$237K 0.11%
+6,797
New +$203K
OLMA icon
206
Olema Pharmaceuticals
OLMA
$1B
$227K 0.1%
+9,069
New +$161K
ZLAB icon
207
Zai Lab
ZLAB
$2.28B
$218K 0.1%
+12,339
New +$289K
PHAT icon
208
Phathom Pharmaceuticals
PHAT
$873M
$214K 0.1%
+12,916
New +$184K
SLSR
209
Solaris Resources
SLSR
$1.18B
$209K 0.09%
26,116
-14,540
-36% -$101K
AYTU icon
210
AYTU BioPharma
AYTU
$23.1M
$206K 0.09%
79,415
+16,963
+27% +$38K
CYTK icon
211
Cytokinetics
CYTK
$10.9B
$204K 0.09%
+3,214
New +$200K
AX icon
212
Axos Financial
AX
$5.66B
$201K 0.09%
2,338
-10,391
-82% -$856K
NVO
213
PUT
Novo Nordisk
NVO
$223B
$198K 0.09%
143
-86
-38% -$4.4K
ZYME icon
214
Zymeworks
ZYME
$1.78B
$193K 0.09%
+7,346
New +$160K
JBIO
215
Jade Biosciences
JBIO
$1.27B
$192K 0.09%
+12,469
New +$146K
IKT icon
216
Inhibikase Therapeutics
IKT
$331M
$192K 0.09%
+93,430
New +$149K
ABUS icon
217
CALL
Arbutus Biopharma
ABUS
$901M
$191K 0.09%
1,484
+292
+24% +$1.31K
SYK icon
218
Stryker
SYK
$123B
$188K 0.08%
+536
New +$195K
PTHS
219
Pelthos Therapeutics
PTHS
$93.8M
$186K 0.08%
6,007
+3,604
+150% +$104K
APGE icon
220
Apogee Therapeutics
APGE
$10.1B
$185K 0.08%
2,445
-12,374
-84% -$779K
IMNM icon
221
Immunome
IMNM
$2.53B
$183K 0.08%
+8,528
New +$150K
KOD icon
222
CALL
Kodiak Sciences
KOD
$2.67B
$182K 0.08%
80
+16
+25% +$328
BHVN icon
223
CALL
Biohaven
BHVN
$2.32B
$181K 0.08%
+536
New +$6.64K
QURE icon
224
PUT
uniQure
QURE
$2.77B
$180K 0.08%
688
– –
ATAI icon
225
AtaiBeckley Inc
ATAI
$2.66B
$180K 0.08%
+43,973
New +$208K
7 8
9
10 11

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Persistent Asset Partners held 464 positions worth $223M, up 53% from $145M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Persistent Asset Partners deployed $48M of net new capital in Q4 2025, opening 223 new positions and adding to 67 existing holdings. Its largest new stake was Molina Healthcare: 51,285 shares worth $8.9M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 49% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was UnitedHealth, an estimated $3.15M trimmed.

  • Persistent Asset Partners's largest Q4 2025 buy was Molina Healthcare: 51,285 shares worth $8.9M.
  • Persistent Asset Partners added most to Elevance Health in Q4 2025, an estimated $5.15M increase.
  • Persistent Asset Partners's biggest Q4 2025 reduction was UnitedHealth, cutting an estimated $3.15M.
  • Persistent Asset Partners fully exited iShares 7-10 Year Treasury Bond ETF in Q4 2025, selling an estimated $4.82M.
  • Persistent Asset Partners's ten largest holdings make up 25% of its $223M portfolio in Q4 2025.
  • Persistent Asset Partners opened 223 new positions and closed 103 in Q4 2025.
  • Persistent Asset Partners's portfolio value rose 53% quarter-over-quarter to $223M.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.